Targeting ACE2 for COVID-19 therapy: opportunities and challenges
The coronavirus disease (COVID-19) pandemic is sweeping the globe. Even with a number
of effective vaccines being approved and available to the public, new cases and escalating …
of effective vaccines being approved and available to the public, new cases and escalating …
[HTML][HTML] Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
ACE2 is the indispensable entry receptor for SARS-CoV and SARS-CoV-2. Because of the
COVID-19 pandemic, it has become one of the most therapeutically targeted human …
COVID-19 pandemic, it has become one of the most therapeutically targeted human …
ACE2: its potential role and regulation in severe acute respiratory syndrome and COVID‐19
COVID‐19, a new disease caused by the 2019‐novel coronavirus (SARS‐CoV‐2), has
swept the world and challenged its culture, economy, and health infrastructure. Forced …
swept the world and challenged its culture, economy, and health infrastructure. Forced …
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19
K Kuba, T Yamaguchi, JM Penninger - Frontiers in immunology, 2021 - frontiersin.org
Seventeen years after the epidemic of SARS coronavirus, a novel coronavirus SARS-CoV-2-
emerged resulting in an unprecedented pandemic. Angiotensin-converting enzyme 2 …
emerged resulting in an unprecedented pandemic. Angiotensin-converting enzyme 2 …
ACE2 in the era of SARS-CoV-2: controversies and novel perspectives
F Saponaro, G Rutigliano, S Sestito… - Frontiers in Molecular …, 2020 - frontiersin.org
Angiotensin-converting enzyme 2 (ACE2) is related to ACE but turned out to counteract
several pathophysiological actions of ACE. ACE2 exerts antihypertensive and …
several pathophysiological actions of ACE. ACE2 exerts antihypertensive and …
[HTML][HTML] Soluble ACE2 as a potential therapy for COVID-19
S Krishnamurthy, RF Lockey… - American Journal of …, 2021 - journals.physiology.org
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat
coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome …
coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome …
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
A recent study by Zoufaly et al. published in The Lancet Respiratory Medicine describes
encouraging data from the first severe COVID-19 patient successfully treated with human …
encouraging data from the first severe COVID-19 patient successfully treated with human …
[HTML][HTML] ACE2 as drug target of COVID-19 virus treatment, simplified updated review
G Mostafa-Hedeab - Reports of biochemistry & molecular biology, 2020 - ncbi.nlm.nih.gov
Background: Since its first appearance in December of 2019, regular updates around the
world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are …
world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are …
ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues
With the emergence of the novel coronavirus SARS-CoV-2 since December 2019, more
than 65 million cases have been reported worldwide. This virus has shown high infectivity …
than 65 million cases have been reported worldwide. This virus has shown high infectivity …
Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …